Garadacimab

Orphan Drug Cold Chain RequiredFDA Approved (2025)

Description

A factor XIIa-inhibiting monoclonal antibody for once-monthly prophylaxis of hereditary angioedema attacks. FDA-approved 2025.

Indications & Therapeutic Use

Hereditary angioedema (prophylaxis)

Linked Diseases:

Hereditary Angioedema
D84.1D054179

Evidence: FDA-approved indication

Global Availability (1 countries)

CountryAccess RouteRegulatory PathwayLead TimeStatus
Standard Marketing AuthorizationApproved

Available Through

This drug is available for procurement through the following fulfilment partner.

Fulfilment Partner
Garadacimab
Generic Namegaradacimab
Brands1 brand available
Active Ingredientgaradacimab
Drug ClassHereditary angioedema (prophylaxis)
ManufacturerCSL Behring
Orphan StatusYes — Orphan Drug
Cold ChainRequired
Reg. StatusFDA Approved (2025)
Countries1 countries
Authority Signals
Last Verified7/24/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations2 Validated Nodes